{"id":"W4211167150","doi":"10.1007/s40257-018-0353-x","title":"Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)","year":2018,"lang":"en","type":"erratum","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Etanercept; Plaque psoriasis; Psoriasis; Clinical trial; Randomized controlled trial; Internal medicine; Dermatology; Pharmacology; Psoriatic arthritis; Tumor necrosis factor alpha; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01242207,0.003151869,0.004218822,0.00347855,0.002284084,0.00528481,0.003972655,0.008219006,0.02915272],"category_scores_gemma":[0.1206778,0.00219622,0.003722508,0.002495448,0.002863799,0.002036323,0.002043585,0.01682496,0.01316626],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005720543,"about_ca_system_score_gemma":0.008761259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01178683,"about_ca_topic_score_gemma":0.01311098,"domain_scores_codex":[0.9876815,0.003109582,0.002422861,0.001472187,0.004283622,0.001030209],"domain_scores_gemma":[0.9289528,0.0266451,0.006002667,0.003382818,0.0312856,0.003731135],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0001534144,0.00001390514,0.00008854851,0.0002478556,0.00005861356,0.0001096221,0.0000149498,0.00003500623,0.00003695467,0.0001550946,0.995424,0.003662134],"study_design_scores_gemma":[0.00113776,0.0001447677,0.002501881,0.001489921,0.0003830609,0.0005773764,0.00009711491,0.0006058009,0.0005338744,0.001371608,0.9910584,0.00009832191],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.00009189407,0.001072851,0.0003246941,0.0423608,0.9550171,0.00004373654,0.000502852,0.0001097144,0.0004763491],"genre_scores_gemma":[0.00592272,0.005617035,0.002828881,0.1353859,0.8009606,0.0004487864,0.001252397,0.0009223989,0.04666117],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02915272,"threshold_uncertainty_score":0.0975256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04548296740520304,"score_gpt":0.4051798012041642,"score_spread":0.3596968337989612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}